April 23, 2020 Hydroxychloroquine Not Recommended for COVID-19 by NIH This week the National Institutes of Health issued treatment guidelines for the management of COVID-19. It does not include the use of pharmaceutical agents for pre or post-exposure prophylaxis, including hydroxychloroquine, except within the confines of a clinical trial. This comes as good news to the rheumatology community. More in this article.   ADVERTISEMENT Abatacept Lowers Diabetes Risk in RA Abatacept (Orencia, Bristol Myers Squibb), a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, appears to lower the risk of diabetes mellitus in patients with rheumatoid arthritis who are receiving biologic or targeted synthetic DMARDs.   Rheumatoid Arthritis News Quiz In this quiz, we highlight new developments in research for rheumatoid arthritis that touch on comorbidities, treatment effectiveness, pregnancy complications and more. Take our quiz here.   Job Opportunities in Rheumatology Visit Rheumatology Network for easy access to new job opportunities in rheumatology. As a service to our readers, we've posted a national "Job Board" in the upper right-hand corner of the site. Suggestions for other content sections? Email the editor at areyes@mmhgroup.com.